ASND Ascendis Pharma A/S

-0.32  -1%
Previous Close 25.35
Open 25.59
Price To book 4.27
Market Cap 811.50M
Shares 32,421,000
Volume 9,365
Short Ratio 8.80
Av. Daily Volume 35,716

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiated August 2016. Enrollment to be completed 4Q 2017.
Growth hormone deficiency in children

Latest News

  1. Ascendis Pharma A/S Reports First Quarter 2017 Financial Results
  2. Ascendis Pharma A/S Announces First Quarter 2017 Financial Results Conference Call on May 23
  3. Ascendis Pharma A/S Announces Upcoming Investor Presentations
  4. Ascendis Pharma A/S :ASND-US: Earnings Analysis: Q4, 2016 By the Numbers : April 20, 2017
  5. Ascendis Pharma A/S Showcases New Data on Rare Disease Product Pipeline at ENDO 2017
  6. Ascendis Pharma A/S Announces Updated Time for April 3 Conference Call to Review ENDO 2017 Data
  7. Ascendis Pharma A/S Announces Conference Call and Webcast to Review Data at ENDO 2017 on April 3
  8. Ascendis Pharma A/S Reports Full Year 2016 Financial Results
  9. Ascendis Pharma A/S Announces Year-End 2016 Financial Results Conference Call on March 22
  10. Ascendis Pharma A/S Announces Multiple Poster Presentations at ENDO 2017
  11. Ascendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients
  12. Ascendis (ASND) Catches Eye: Stock Gains 7.2% in Session
  13. Ascendis Pharma A/S Announces Presentation at the LEERINK Partners 6th Annual Global Healthcare Conference on February 15th
  14. Ascendis Pharma A/S Announces Presentation at 35th Annual J.P. Morgan Healthcare Conference on January 9
  15. Blog Coverage Intercept Pharma Receives European Approval for the Treatment of a Rare Liver Condition
  16. Why Ascendis Pharma (ASND) Stock Might be a Great Pick
  17. Are Hedge Funds On To Something With Ascendis Pharma A/S (ASND) Bullishness?
  18. Ascendis Pharma A/S :ASND-US: Earnings Analysis: Q3, 2016 By the Numbers : December 2, 2016
  19. Edited Transcript of ASND earnings conference call or presentation 30-Nov-16 9:30pm GMT
  20. Baxter International (BAX) Q3 Earnings: Beat in the Cards?